期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

他汀类药对肝脏影响的新进展 被引量：3

下载PDF
导出
摘要 他汀类药（statins）是羟甲基戊二酰辅酶A（HMG-CoA）还原酶抑制剂,不仅可抑制内源性胆固醇合成,还具有抗炎、抗氧化和抗纤维化等多种活性.他汀类药是目前最为经典和有效的抗动脉粥样硬化药物,被广泛应用于多种动脉粥样硬化性心血管疾病或高脂血症的治疗. 不良反应方面,他汀类药对肝脏功能的影响深受医生与患者关注.而有越来越多的证据表明,他汀类药对肝脏的风险并没有之前人们认为的那样严重,相对于心血管疾病的发病和死亡风险,一些以前曾被认为是他汀类药禁忌证的患者可能不应放弃或中止他汀类药治疗.本文将对近年来他汀类药对肝脏功能影响的文献做一综述.
作者 刘晓 梁雁 周颖 崔一民
机构地区 北京大学第一医院药剂科
出处 《中国医院用药评价与分析》 2014年第2期106-108,共3页 Evaluation and Analysis of Drug-use in Hospitals of China
关键词 他汀类药 肝脏功能 动脉粥样硬化性心血管疾病 抗动脉粥样硬化药物 还原酶抑制剂 羟甲基戊二酰 死亡风险 胆固醇合成
分类号 R972.6 [医药卫生—药品]
  • 相关文献

参考文献22

  • 1严晓伟.他汀类药物的肝脏安全性[J].中华心血管病杂志,2011,39(3):201-202. 被引量：17
  • 2Han HK, Rha SW, Kang HJ, et al. Evaluation of shortterm safety and efficacy of HMG-CoA reductase inhibitors in hypercholesterolemic patients with elevated serum alanine transaminase concentrations:PITCH study(PITavastatin versus atorvastatin to evaluate the effect on patients with hypercholesterolemia and mild to moderate hepatic damage) [J]. J Clin Lipidol. 2012 ,6( 4) :340-351.
  • 3Berkelhammer C, Lerma EV. Statin treatment in patients with elevated liver enzymes: pitch to proceed [J]. J Clin Lipidol ,2012,6 (4) :310-311.
  • 4Ekstedt M, Franzen L, Mathiesen UL, et al. Statins in nonalcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study [J]. J Hepatol ,2007,47 (I) : 135-141.
  • 5Rallidis LS, Drakoulis CK, Parasi AS. Pravastatin in patients with non-alcoholic steatohepatitis , results of a pilot study[J]. Atherosclerosis ,2004, 174 ( 1) : 193-196.
  • 6Hyogo H, Tazuma S, Arihiro K, et al. Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia [J]. Metabolism,2008 ,57 (12) : 1711-1718.
  • 7Avins AL,Manos MM,Ackerson L,et al. Hepatic effects of lovastatin exposure in patients with liver disease: A retrospective cohort study [J]. Drug Safety, 2008 ,31 ( 4 ) : 325-334.
  • 8Chalasani N, Aljadhey H, Kesterson J, et al. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity [J]. Gastroenterology, 2004,126 (5) : 1287- 1292.
  • 9Vuppalanchi R, Teal E, Chalasani N. Patients with elevated baseline liver enzymes do not have higher frequency of hepatotoxicity from lovastatin than those with normal baseline liver enzymes [J]. Am J Med Sci, 2005 , 329(2) :62-65.
  • 10Lewis JH, Mortensen ME, Zweig S, et al. Efficacy and safety of high -dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial [J]. Hepatology, 2007,46(5) :1453-1463.

二级参考文献4

  • 1Chalasani N,Aljadhey H,Kesterson J,et al.Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity.Gastroenterology,2004,126:1287-1292.
  • 2Khorashadi S,Hasson NK,Cheung RC.Incidence of statin hepatotoxicity in patients with hepatitis C.Clin Gastroenterol Hepatol,2006,4:902-907.
  • 3de Denus S,Spinler SA,Miller K,et al.Statins and liver toxicity:a meta-analysis.Pharmacotherapy,2004,24:584-591.
  • 4Russo MW,Galanko JA,Shrestha R,et al.Liver transplantation for acute liver failure from drug induced liver injury in the United States.Liver Transpl,2004,10:1018-1023.

共引文献16

同被引文献31

引证文献3

二级引证文献10

中国医院用药评价与分析
2014年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部